2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
256
INDUSTRY
30
OTHER_GOV
11
UNKNOWN
1
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Dermatologic
1
Conditions
Melanoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Radiotherapy
302
Cisplatin
266
Cyclophosphamide
230
Doxorubicin
177
Paclitaxel
170
Vincristine
162
Carboplatin
152
Filgrastim
140
Etoposide
139
Gemcitabine
118
Docetaxel
114
Fluorouracil
113
Methotrexate
106
Dexamethasone
106
Cytarabine
106
Prednisone
92
Leucovorin
90
Gene Expression Profiling
82
Granulocyte Colony-Stimulating Factor
75
Specimen Handling
70
Magnetic Resonance Spectroscopy
63
Irinotecan
59
Capecitabine
59
Radiation
54
Polymerase Chain Reaction
51
Ifosfamide
51
Rituximab
49
Immunohistochemistry
49
Daunorubicin
49
Oxaliplatin
48
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Immune Checkpoint Inhibitors
×
Clear all
NCT05522660
2026-04-27
USZ-STRIKE
ETOP IBCSG Partners Foundation
Phase 3
Recruiting
180 enrolled